Journal Article

Therapeutic modulation of allergic airways disease with leukotriene receptor antagonists

G.P. Currie, P. Srivastava, O.J. Dempsey and D.K.C. Lee

in QJM: An International Journal of Medicine

Published on behalf of Association of Physicians of Great Britain and Ireland

Volume 98, issue 3, pages 171-182
Published in print March 2005 | ISSN: 1460-2725
Published online March 2005 | e-ISSN: 1460-2393 | DOI: https://dx.doi.org/10.1093/qjmed/hci024
Therapeutic modulation of allergic airways disease with leukotriene receptor antagonists

Show Summary Details

Preview

Although asthma is one of the most common chronic respiratory conditions, it often remains unrecognized and undertreated, while patients are often reluctant to comply with regular inhaled anti-inflammatory and bronchodilator therapy. Allergic rhinitis co-exists with asthma in as many as 40% of patients, and can be regarded as a continuum of the same inflammatory disease process. Corticosteroids are the ‘gold standard’ first-line treatment for both conditions, and have a significant impact upon underlying inflammation, symptoms and long-term outcome. Cysteinyl leukotrienes are potent airway inflammatory mediators, suggesting that treatment antagonizing their effects could play a role in disease management. In recent years, leukotriene receptor antagonists have provided a further therapeutic option in the management of allergic airways disease. These drugs are orally active, can be administered once daily, and provide a systemic approach to the management of patients with asthma and allergic rhinitis. We review the pharmacology of leukotriene receptor antagonists, their potential role in clinical practice in patients with allergic airways disease, and likely areas for further research.

Journal Article.  7477 words.  Illustrated.

Subjects: Medicine and Health

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.